EUVIMEDEUVIMED entdecken
Open Access

Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer’s disease

Hyun-Sik Yang, Wai-Ying Wendy Yau iD, Becky C Carlyle iD, Bianca A Trombetta, Can Zhang, Zahra Shirzadi, Aaron P Schultz, Jeremy J Pruzin, Colleen D Fitzpatrick, Dylan R Kirn, Jennifer S Rabin iD, Rachel F Buckley iD und 7 weitere

Brain · 03.06.2024 · 147 (6) · 2158-2168

DOI: 10.1093/brain/awae034 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain, online erschienen am 05.02.2024. Verfasst von Hyun-Sik Yang und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Vascular Endothelial Growth Factor A, tau Proteins, Cognition. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, NCRR NIH HHS, Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Vascular dysfunction is increasingly recognized as an important contributor to the pathogenesis of Alzheimer’s disease. Alterations in vascular endothelial growth factor (VEGF) pathways have been implicated as potential mechanisms. However, the specific impact of VEGF proteins in preclinical Alzheimer’s disease and their relationships with other Alzheimer’s disease and vascular pathologies during this critical early period remain to be elucidated. We included 317 older adults from the Harvard Aging Brain Study, a cohort of individuals who were cognitively unimpaired at baseline and followed longitudinally for up to 12 years. Baseline VEGF family protein levels (VEGFA, VEGFC, VEGFD, PGF and FLT1) were measured in fasting plasma using high-sensitivity immunoassays. Using linear mixed effects models, we examined the interactive effects of baseline plasma VEGF proteins and amyloid PET burden (Pittsburgh Compound-B) on longitudinal cognition (Preclinical Alzheimer Cognitive Composite-5). We further investigated if effects on cognition were mediated by early neocortical tau accumulation (flortaucipir PET burden in the inferior temporal cortex) or hippocampal atrophy. Lastly, we examined the impact of adjusting for baseline cardiovascular risk score or white matter hyperintensity volume. Baseline plasma VEGFA and PGF each showed a significant interaction with amyloid burden on prospective cognitive decline. Specifically, low VEGFA and high PGF were associated with greater cognitive decline in individuals with elevated amyloid, i.e. those on the Alzheimer’s disease continuum. Concordantly, low VEGFA and high PGF were associated with accelerated longitudinal tau accumulation in those with elevated amyloid. Moderated mediation analyses confirmed that accelerated tau accumulation fully mediated the effects of low VEGFA and partially mediated (31%) the effects of high PGF on faster amyloid-related cognitive decline. The effects of VEGFA and PGF on tau and cognition remained significant after adjusting for cardiovascular risk score or white matter hyperintensity volume. There were concordant but non-significant associations with longitudinal hippocampal atrophy. Together, our findings implicate low VEGFA and high PGF in accelerating early neocortical tau pathology and cognitive decline in preclinical Alzheimer’s disease. Additionally, our results underscore the potential of these minimally-invasive plasma biomarkers to inform the risk of Alzheimer’s disease progression in the preclinical population. Importantly, VEGFA and PGF appear to capture distinct effects from vascular risks and cerebrovascular injury. This highlights their potential as new therapeutic targets, in combination with anti-amyloid and traditional vascular risk reduction therapies, to slow the trajectory of preclinical Alzheimer’s disease and delay or prevent the onset of cognitive decline.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseVascular Endothelial Growth Factor Atau ProteinsCognitionHumansMaleFemaleAgedLongitudinal StudiesAged, 80 and overPositron-Emission TomographyCognitive DysfunctionBiomarkers

Stichwörter der Autor:innen

VCIDangiogenesisbiomarkerdementia

Substanzen

Vascular Endothelial Growth Factor Atau ProteinsVEGFA protein, humanBiomarkers

Autor:innen und Institutionen

  • Department of Neurology, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Center for Alzheimer Research and Treatment, Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA.
  • Harvard Medical School, Boston, MA 02115, USA.
  • Alzheimer's Clinical and Translational Research Unit, Department of Neurology, Massachusetts General Hospital, Charlestown, MA 02129, USA.
  • Department of Physiology, Anatomy and Genetics, Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford OX1 3PT, UK.
  • Genetics and Aging Research Unit, McCance Center for Brain Health, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA.

ORCID-Profile: Wai-Ying Wendy Yau, Becky C Carlyle, Jennifer S Rabin, Rachel F Buckley, Timothy J Hohman, Keith A Johnson, Jasmeer P Chhatwal

Förderung

  • NIA NIH HHS
  • NCRR NIH HHS
  • Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital
  • American Brain Foundation
  • NIH HHS
  • American Academy of Neurology
  • Doris Duke Charitable Foundation
  • NIBIB NIH HHS

Zitieren

APA

Yang, H. S., Yau, W. W., Carlyle, B. C., Trombetta, B. A., Zhang, C., Shirzadi, Z., Schultz, A. P., Pruzin, J. J., Fitzpatrick, C. D., Kirn, D. R., Rabin, J. S., Buckley, R. F., Hohman, T. J., Rentz, D. M., Tanzi, R. E., Johnson, K. A., Sperling, R. A., Arnold, S. E., & Chhatwal, J. P. (2024). Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer’s disease. Brain, 147(6), 2158-2168. https://doi.org/10.1093/brain/awae034

Vancouver

Yang HS, Yau WW, Carlyle BC, Trombetta BA, Zhang C, Shirzadi Z, et al. Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer’s disease. Brain. 2024;147(6):2158-2168. doi:10.1093/brain/awae034

BibTeX
@article{Yang2024,
  author = {Yang, Hyun-Sik and Yau, Wai-Ying Wendy and Carlyle, Becky C and Trombetta, Bianca A and Zhang, Can and Shirzadi, Zahra and Schultz, Aaron P and Pruzin, Jeremy J and Fitzpatrick, Colleen D and Kirn, Dylan R and Rabin, Jennifer S and Buckley, Rachel F and Hohman, Timothy J and Rentz, Dorene M and Tanzi, Rudolph E and Johnson, Keith A and Sperling, Reisa A and Arnold, Steven E and Chhatwal, Jasmeer P},
  title = {Plasma VEGFA and PGF impact longitudinal tau and cognition in preclinical Alzheimer’s disease},
  journal = {Brain},
  year = {2024},
  volume = {147},
  number = {6},
  pages = {2158--2168},
  doi = {10.1093/brain/awae034}
}
Kostenlos starten →